NeoGenomics Inventory 2010-2025 | NEO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

NeoGenomics inventory from 2010 to 2025. Inventory can be defined as the total value of inventories in all stages of completion.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

NeoGenomics inventory from 2010 to 2025. Inventory can be defined as the total value of inventories in all stages of completion.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$220.6B
Amgen (AMGN)	$158.8B
Gilead Sciences (GILD)	$136.4B
Vertex Pharmaceuticals (VRTX)	$120.4B
Bristol Myers Squibb (BMY)	$95.4B
GSK (GSK)	$78.4B
CSL (CSLLY)	$76.6B
Regeneron Pharmaceuticals (REGN)	$61.3B
Alnylam Pharmaceuticals (ALNY)	$41.1B
Argenex SE (ARGX)	$34.2B
BioNTech SE (BNTX)	$27.1B
Royalty Pharma (RPRX)	$20.2B
Biogen (BIIB)	$19.7B
Insmed (INSM)	$18.6B
Illumina (ILMN)	$15.7B
Genmab (GNMSF)	$14.2B
Genmab (GMAB)	$13.7B
Incyte (INCY)	$13.3B
Moderna (MRNA)	$13B
Exelixis (EXEL)	$12.2B
BioMarin Pharmaceutical (BMRN)	$11.1B
QIAGEN (QGEN)	$10.7B
Ascendis Pharma (ASND)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.4B
Exact Sciences (EXAS)	$9.8B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Bio-Techne Corp (TECH)	$8.5B
Blueprint Medicines (BPMC)	$8.4B
Roivant Sciences (ROIV)	$7.7B
Repligen (RGEN)	$7.3B